Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Valbenazine 40 mg Through Week 4	0	163
Total, all-cause mortality	Valbenazine 40mg Week 4 Through Week 52	0	35
Total, all-cause mortality	Valbenazine 80mg Week 4 Through Week 52	1	107
Total, all-cause mortality	Valbenazine 80/40mg Week 4 Through Week 52	0	11
Total, other adverse events	Valbenazine 40 mg Through Week 4	0	163
Total, other adverse events	Valbenazine 40mg Week 4 Through Week 52	5	35
Total, other adverse events	Valbenazine 80mg Week 4 Through Week 52	15	107
Total, other adverse events	Valbenazine 80/40mg Week 4 Through Week 52	1	11
Total, serious adverse events	Valbenazine 40 mg Through Week 4	0	163
Total, serious adverse events	Valbenazine 40mg Week 4 Through Week 52	3	35
Total, serious adverse events	Valbenazine 80mg Week 4 Through Week 52	17	107
Total, serious adverse events	Valbenazine 80/40mg Week 4 Through Week 52	1	11

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02405091/event-totals